Novan Therapeutics is a privately held, clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies.  Novan’s core technologies solve the previous delivery issues with nitric oxide by stably storing the gaseous species on macromolecules that result in a diverse pipeline of timed-release nitric oxide-releasing new chemical entities.  The company's lead product candidate, SB204, is an investigational drug product in late-stage development as a new treatment for acne vulgaris and is anticipated to enter Phase 3 clinical testing by Q1 2016.  SB206, a topical anti-viral to treat external genital warts due to human papilloma virus (HPV) infection, is expected to enter Phase 2 studies by mid-2015.

Learn More about Novan Therapeutics

Close
Close